303 related articles for article (PubMed ID: 20876889)
1. AGEs and diabetic retinopathy.
Stitt AW
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):4867-74. PubMed ID: 20876889
[TBL] [Abstract][Full Text] [Related]
2. AGEs, RAGE, and diabetic retinopathy.
Zong H; Ward M; Stitt AW
Curr Diab Rep; 2011 Aug; 11(4):244-52. PubMed ID: 21590515
[TBL] [Abstract][Full Text] [Related]
3. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T
Curr Drug Discov Technol; 2006 Mar; 3(1):83-8. PubMed ID: 16712466
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end products and diabetic retinopathy.
Chen M; Curtis TM; Stitt AW
Curr Med Chem; 2013; 20(26):3234-40. PubMed ID: 23745547
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy.
Stitt AW; Frizzell N; Thorpe SR
Curr Pharm Des; 2004; 10(27):3349-60. PubMed ID: 15544520
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products.
Maeda S; Matsui T; Ojima A; Takeuchi M; Yamagishi S
Nutr Res; 2014 Sep; 34(9):807-13. PubMed ID: 25241332
[TBL] [Abstract][Full Text] [Related]
8. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
[TBL] [Abstract][Full Text] [Related]
9. Pathological Perturbations in Diabetic Retinopathy: Hyperglycemia, AGEs, Oxidative Stress and Inflammatory Pathways.
Sahajpal NS; Goel RK; Chaubey A; Aurora R; Jain SK
Curr Protein Pept Sci; 2019; 20(1):92-110. PubMed ID: 30264677
[TBL] [Abstract][Full Text] [Related]
10. Diabetes-related adduct formation and retinopathy.
Stitt AW; Curtis TM
J Ocul Biol Dis Infor; 2011 Jun; 4(1-2):10-8. PubMed ID: 23272270
[TBL] [Abstract][Full Text] [Related]
11. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
12. RAGE and its ligands in retinal disease.
Barile GR; Schmidt AM
Curr Mol Med; 2007 Dec; 7(8):758-65. PubMed ID: 18331234
[TBL] [Abstract][Full Text] [Related]
13. The role of advanced glycation in the pathogenesis of diabetic retinopathy.
Stitt AW
Exp Mol Pathol; 2003 Aug; 75(1):95-108. PubMed ID: 12834631
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets.
Safi SZ; Qvist R; Kumar S; Batumalaie K; Ismail IS
Biomed Res Int; 2014; 2014():801269. PubMed ID: 25105142
[TBL] [Abstract][Full Text] [Related]
15. Involvement of Advanced Glycation End Products in the Pathogenesis of Diabetic Retinopathy.
Xu J; Chen LJ; Yu J; Wang HJ; Zhang F; Liu Q; Wu J
Cell Physiol Biochem; 2018; 48(2):705-717. PubMed ID: 30025404
[TBL] [Abstract][Full Text] [Related]
16. Advanced glycation end products, their receptors and diabetic angiopathy.
Wautier JL; Guillausseau PJ
Diabetes Metab; 2001 Nov; 27(5 Pt 1):535-42. PubMed ID: 11694852
[TBL] [Abstract][Full Text] [Related]
17. Relation between polymorphisms G1704T and G82S of RAGE gene and diabetic retinopathy in Japanese type 2 diabetic patients.
Kashiwagi A; Araki S
Intern Med; 2005 May; 44(5):397-8. PubMed ID: 15942078
[No Abstract] [Full Text] [Related]
18. Advanced Glycation End-Products and Diabetic Neuropathy of the Retina.
Oshitari T
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769249
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy.
Yamagishi S; Matsui T
Curr Pharm Biotechnol; 2011 Mar; 12(3):362-8. PubMed ID: 20939798
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation and retinal pathology during diabetes.
Stitt AW; Curtis TM
Pharmacol Rep; 2005; 57 Suppl():156-68. PubMed ID: 16415497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
